Skip to main content

This website is intended exclusively for healthcare professionals residing and/or working in Kuwait.

Home | go to homepage
SCIENCE
  • SCIENCE
  • Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
  • Anti-Infectives
  • Asthma
  • Atopic Dermatitis
  • Cardiovascular
    • Cardiovascular
    • Atherothrombosis
    • Dyslipidemia
    • Hypertension
    • Thrombosis
  • Chronic Obstructive Pulmonary Disease
  • Diabetes
  • Eosinophilic Esophagitis
  • Multiple Myeloma
  • Multiple Sclerosis
  • Nasal Polyps
  • Neurological Disorders
  • Prurigo Nodularis
  • Rare Diseases
  • Vaccines
    • Vaccines
    • Influenza
    • Meningitis
    • Pertussis & Polio
    • RSV
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Atopic Dermatitis
  • Cardiovascular
  • Diabetes
    • Diabetes
    • Tools And Resources
      • Tools And Resources
      • My Dose Coach
      • Toujeo Welcome Pack
      • Soliqua Welcome Pack
      • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
      • Clinical and economic value of SOLIQUA - Pharmacist perspective
  • Nasal Polyps
  • Rare Diseases
PRODUCTS
  • PRODUCTS
  • Aldurazyme®
    • Aldurazyme®
    • Dosing Calculator
  • Amaryl®
  • Apidra®
  • Aprovel®
  • Aubagio®
    • Aubagio®
    • Aubagio vs Ofatumumab
  • Cerezyme
  • Clexane®
  • Depakine®
  • Dupixent®
    • Dupixent®
    • Atopic Dermatitis
    • Asthma
    • Eosinophilic Esophagitis
    • Nasal Polyps
  • Fabrazyme®
    • Fabrazyme®
    • Quantifying the Effect of Fabrazyme
    • Canadian Fabry Disease Initiative
    • Long Term Renal Function
  • Lantus®
  • Lemtrada®
  • Myozyme®
  • Nexviazyme
  • Plavix®
  • Praluent
    • Praluent
    • Praluent®
    • Praluent 300 mg
  • Renvela®
  • Sarclisa
    • Sarclisa
    • Sarclisa®
    • Sarclisa Kd®
    • Sarclisa Pd®
  • Soliqua®
    • Soliqua®
    • SoliMix Study
    • For a Peaceful Ramadan
    • Soli-Simplify Study
    • Soliqua®
    • Soliqua Safety®
    • Soliqua Simplicity®
    • Soliqua Guidelines®
    • Soliqua Data Set®
  • Tavanic®
  • Toujeo®
    • Toujeo®
    • Wall of Evidence
    • Toujeo T2DM
    • Toujeo T1DM
    • Toujeo Innovation
    • Toujeo for a Peaceful Ramadan
    • How to Start
    • Time-in-Range
  • Xatral®
  • Zympass®
EVENTS
  • LOGIN
  • SIGN UP
  • SEARCH
    Home | go to homepage
  • LOGIN
  • SIGN UP
  • SEARCH
    Home | go to homepage
    SCIENCE
    • SCIENCE
    • Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
    • Anti-Infectives
    • Asthma
    • Atopic Dermatitis
    • Cardiovascular
      • Cardiovascular
      • Atherothrombosis
      • Dyslipidemia
      • Hypertension
      • Thrombosis
    • Chronic Obstructive Pulmonary Disease
    • Diabetes
    • Eosinophilic Esophagitis
    • Multiple Myeloma
    • Multiple Sclerosis
    • Nasal Polyps
    • Neurological Disorders
    • Prurigo Nodularis
    • Rare Diseases
    • Vaccines
      • Vaccines
      • Influenza
      • Meningitis
      • Pertussis & Polio
      • RSV
    PATIENT SUPPORT
    • PATIENT SUPPORT
    • Atopic Dermatitis
    • Cardiovascular
    • Diabetes
      • Diabetes
      • Tools And Resources
        • Tools And Resources
        • My Dose Coach
        • Toujeo Welcome Pack
        • Soliqua Welcome Pack
        • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
        • Clinical and economic value of SOLIQUA - Pharmacist perspective
    • Nasal Polyps
    • Rare Diseases
    PRODUCTS
    • PRODUCTS
    • Aldurazyme®
      • Aldurazyme®
      • Dosing Calculator
    • Amaryl®
    • Apidra®
    • Aprovel®
    • Aubagio®
      • Aubagio®
      • Aubagio vs Ofatumumab
    • Cerezyme
    • Clexane®
    • Depakine®
    • Dupixent®
      • Dupixent®
      • Atopic Dermatitis
      • Asthma
      • Eosinophilic Esophagitis
      • Nasal Polyps
    • Fabrazyme®
      • Fabrazyme®
      • Quantifying the Effect of Fabrazyme
      • Canadian Fabry Disease Initiative
      • Long Term Renal Function
    • Lantus®
    • Lemtrada®
    • Myozyme®
    • Nexviazyme
    • Plavix®
    • Praluent
      • Praluent
      • Praluent®
      • Praluent 300 mg
    • Renvela®
    • Sarclisa
      • Sarclisa
      • Sarclisa®
      • Sarclisa Kd®
      • Sarclisa Pd®
    • Soliqua®
      • Soliqua®
      • SoliMix Study
      • For a Peaceful Ramadan
      • Soli-Simplify Study
      • Soliqua®
      • Soliqua Safety®
      • Soliqua Simplicity®
      • Soliqua Guidelines®
      • Soliqua Data Set®
    • Tavanic®
    • Toujeo®
      • Toujeo®
      • Wall of Evidence
      • Toujeo T2DM
      • Toujeo T1DM
      • Toujeo Innovation
      • Toujeo for a Peaceful Ramadan
      • How to Start
      • Time-in-Range
    • Xatral®
    • Zympass®
    EVENTS
  • LOGIN
  • SIGN UP
  • SEARCH
    • Home
    • Science
    • Cutting-Edge Science

    Science at Sanofi

    Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas

    Filters

    Therapeutical Areas
    Cardiovascular
    Diabetes
    Asthma
    Atopic Dermatitis
    Nasal Polyps
    Rare diseases
    Vaccines
    Influenza
    Pertussis & Polio
    Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
    Eosinophilic Esophagitis
    Multiple Myeloma
    Type of Content
    Watch
    Listen
    Read

    Hypercholesterolemia Treatment Patterns and Lipid Target in ACS Patients

    Treatment simplification in T2D: A less-is-more approach to help reduce the burden of disease

    Advancing Therapy with iGlarLixİ

    Treatment simplification in T2D: Unmet needs in people with T2D

    Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study

    Diagnostic Algorithm for Gaucher Disease in Pediatric

    Professor Tawfeq Ben Omran video on ASMD

    Gaucher disease awareness month video

    Pompe don’t lose time video

    MPSI chase the signs video

    Professor Moeen Al Sayed video on ASMD

    Diagnostic Algorithm for Gaucher Disease in Adult

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    Home | go to homepage

    SANOFI, Level 3, One JLT, Jumeirah Lake Towers (JLT), DMCC, PO Box 53899, Dubai, UAE |

    Tel.: +971 4 550 3600 | Fax: +971 4 5521050

    For further Medical Information:

    please contact: +971 565776791 or Email: medical-information.gulf@sanofi.com

    To report an adverse event:

    please call: +971 561747001 or Email: Gulf.pharmacovigilance@sanofi.com

    To report any product technical complaints, kindly contact: Email: quality.greatergulf@sanofi.com

     

    MAT-KW-2100295-V5-May-23

    • Legal notice
    • Cookie policy
    • Privacy policy
    • Sitemap
    • Change country

    YOU WILL NOW BE LEAVING THE SITE

    By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
    Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.

    Continue
    This website is intended exclusively for healthcare professionals residing and/or working in Kuwait.
     
    Please choose if you are a healthcare professional and wish to continue on this site or if you are a member of the public to be redirected to the Sanofi website.